BioSpace News Archive

CG Oncology, Inc. announced that three abstracts highlighting cretostimogene will be presented at the American Urological Association Annual Meeting, taking place at Henry B. González Convention Center in San Antonio, TX from May 3-6, 2024.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.

Labcorp and OPKO Health, Inc. announced that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health.

Verix, a leading AI-powered pharmaceutical commercial operations enhancement platform provider, announced the launch of its “GenAI Database Explorer,” a capability designed to revolutionize the exploration of commercial pharmaceutical data.

Laxxon Medical, a leading pharma-technology company pioneering a new generation of advanced pharmaceuticals, announced today their participation as a private company in the 23rd Annual Needham Virtual Healthcare Conference on April 8-11, 2024.

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting.

Bio-Techne Corporation is pleased to announce that Lunaphore, part of Bio-Techne’s Spatial Biology Division, is partnering with Nikon Instruments Inc. to expand access to spatial biology services with the COMET™ platform for US-based biotech, pharma, and academic customers.

Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced its expansion into autoimmune diseases with MB-106, a personalized CD20-targeted, 3rd-generation autologous CAR T-cell therapy.

Headlands Research, a leading multinational network of clinical trial sites, announced a fifth site, Headlands Research Orlando, as part of its partnership with Pfizer to create multiple clinical trial sites in areas with highly diverse demographics.

Personalis, Inc. (Nasdaq: PSNL) announced today that a podium talk and multiple abstracts featuring data for the company’s NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA detection will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California, April 5-10, 2024.